PD-1/L1

FDA
Pharma

FDA challenges broad use of PD-1 drugs in stomach cancer

The FDA is considering a class-wide action against PD-1 inhibitors in stomach cancer and esophageal cancer based on findings from multiple trials.
Angus Liu Sep 24, 2024 2:30pm
Product image of Exelixis 60mg Cabometyx

Exelixis plots FDA prostate cancer filing despite survival miss

Sep 16, 2024 5:00pm
Imfinzi

AZ's perioperative Imfinzi extends life in bladder cancer type

Sep 15, 2024 10:30am
Keytruda

Merck's Keytruda helps early-stage TNBC patients live longer

Sep 15, 2024 8:10am
Incyte CEO Herv Hoppenot

Incyte CEO views PD-1 drug Zynyz as oncology pipeline aide

Sep 14, 2024 10:30am
liver

Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype

Sep 14, 2024 10:30am